Every laboratory result that reaches a clinician carries an implicit claim: that the measurement was performed correctly, by qualified personnel, using validated methods, on a specimen handled appropriately, and reported through a system designed to prevent the result from reaching the wrong patient or being misinterpreted. That claim is only credible if the laboratory making it operates within an accreditation framework that independently verifies it. Laboratory accreditation standards are the structured requirements against which those independent verifications are performed, and understanding what CLIA, CAP, and ISO 15189 each require, how they relate to one another, and what they collectively mean for laboratory quality is essential knowledge for anyone involved in or dependent on clinical laboratory medicine.
Laboratory accreditation standards exist because the consequences of laboratory errors are real, direct, and documentable. A laboratory that reports an inaccurate potassium because its quality control process was inadequate, an incorrect blood type because patient identification procedures failed, or a missed malignancy because a slide was interpreted without adequate proficiency can cause patient harm that is traceable back to the absence of functioning quality systems. Accreditation does not guarantee that errors will never occur. It provides the framework of documented procedures, competency verification, proficiency testing, and ongoing quality monitoring that makes errors far less likely and, when they do occur, more detectable and correctable.
As of March 2024, the Centers for Medicare and Medicaid Services (CMS) CLIA database contained records for more than 317,545 certified laboratory facilities in the United States, representing one of the world’s most extensive regulated laboratory networks. Globally, approximately 12,000 laboratories across 86 accreditation bodies have achieved ISO 15189 accreditation through ILAC mutual recognition arrangements, with their certificates accepted in over 80 countries. The College of American Pathologists serves more than 20,000 laboratories worldwide through its accreditation and proficiency testing programs. These numbers reflect the institutional infrastructure that laboratory accreditation has built over decades of iterative regulatory development.
CLIA: The Federal Baseline for US Clinical Laboratories
The Clinical Laboratory Improvement Amendments of 1988, universally known as CLIA, represent the foundational federal regulatory framework for any laboratory testing human specimens in the United States. Enacted by Congress and implemented through the CMS in partnership with the CDC and FDA, CLIA establishes the minimum quality requirements that all US clinical laboratories must meet, regardless of their size, setting, or ownership structure. Compliance with CLIA is not voluntary. Any laboratory performing testing on human specimens to provide information for diagnosis, prevention, treatment, or assessment of disease must have a CLIA certificate to legally operate and receive Medicare and Medicaid reimbursement.
CLIA organizes laboratories and their testing activities by complexity, a classification system that determines which regulatory requirements apply. The certificate of waiver covers tests categorized by the FDA as simple with low risk of error, including urine dipstick urinalysis, blood glucose monitoring devices cleared for home use, and rapid antigen tests for influenza and COVID-19. These tests require minimal regulatory oversight because the risk of a clinically consequential error from their use is low. As of March 2024, approximately 244,791 laboratories, roughly 80 percent of all non-exempt CLIA-certified facilities, held waiver certificates, reflecting the enormous volume of simple testing performed across physician office laboratories, urgent care clinics, pharmacies, and community health settings.
Provider-performed microscopy procedures represent a second certificate category covering microscopic examinations performed during the patient encounter, such as direct wet mounts, fecal leukocyte examinations, and KOH preparations. The 25,682 facilities holding this certificate type as of March 2024 face a defined but limited set of requirements reflecting the moderate complexity of the examinations involved.
The most consequential CLIA categories are moderate and high complexity testing, governed by certificates of compliance and certificates of accreditation. These cover the full range of tests performed in clinical chemistry, hematology, coagulation, immunohematology, microbiology, molecular diagnostics, cytology, and anatomical pathology. CLIA requirements for these laboratories cover six domains: patient test management, quality control, proficiency testing, quality assurance, personnel qualifications, and laboratory director responsibilities. Personnel requirements specify the educational and experiential qualifications for laboratory directors, technical supervisors, clinical consultants, general supervisors, and testing personnel, calibrated to the complexity level of the testing performed.
The CLIA proficiency testing requirement mandates that laboratories performing non-waived testing enroll in an approved PT program for regulated analytes and demonstrate acceptable performance. The first major update to CLIA proficiency testing regulations since 1992 was published as a final rule in July 2022, with key implementation dates in 2025 establishing new analytes and updated acceptance limits. The CAP GH5 HbA1c survey data for 2024 reported overall pass rates for participating laboratories ranging from 96.7 to 98.2 percent, with method-specific performance variability highlighting why ongoing PT participation remains essential for identifying outlier performance before it affects patient results.
A critical regulatory nuance in the CLIA framework is that laboratories in the two CLIA-exempt states, New York and Washington, operate under state laboratory regulations deemed equivalent to or more stringent than CLIA. These states conduct their own inspections and issue their own certificates, and their laboratories do not appear in the standard CMS CLIA statistics as regulated under federal oversight.
CAP Accreditation: Exceeding the Federal Floor
The College of American Pathologists is the largest professional organization of board-certified pathologists in the United States and the leading provider of laboratory accreditation and proficiency testing programs globally. CAP has offered accreditation since 1964 and was formally granted CMS-deemed status under CLIA, meaning CAP-accredited laboratories are considered to meet CLIA requirements through CAP’s inspection process rather than through the standard CMS compliance pathway.
The critical distinction between CLIA certification and CAP accreditation is that CLIA compliance is mandatory while CAP accreditation is voluntary. A laboratory seeking CAP accreditation is choosing to subject itself to a more rigorous quality assessment than federal law requires. In practice, CAP requirements consistently exceed CLIA standards across multiple domains, and laboratories in clinical pathology, anatomical pathology, and molecular diagnostics that seek the highest level of credibility and quality accountability routinely pursue CAP accreditation.
The mechanism of CAP accreditation is the peer inspection, conducted by teams of laboratory professionals and pathologists who visit the laboratory, review documentation, observe operations, and evaluate compliance against discipline-specific checklists. CAP maintains checklists across all major laboratory disciplines, and these checklists are updated annually to incorporate regulatory changes, clinical evidence, and technological advances. The 2024 edition of the CAP Laboratory Accreditation Program checklists integrated the CLIA final rule changes that took effect in December 2024, including revised personnel qualification requirements, new director onsite visit frequency requirements, and updated immunohistochemistry predictive marker standards aligned with newly published CAP evidence-based guidelines. Inspections occur every two years, with laboratories conducting self-inspections in alternating years using the same checklists their external inspectors will use.
CAP’s proficiency testing programs represent a parallel and complementary pillar of its quality assurance infrastructure. The CAP PT catalog spans more than 700 programs across 16 disciplines, all developed by expert scientific committees and updated to reflect current testing platforms and clinical standards. In 2026, CAP launched 21 new PT and external quality assessment programs, expanding coverage to areas including transfusion safety testing and infectious disease detection, specifically framing these additions as advances in laboratory quality that support better patient outcomes. Laboratories enrolled in CAP PT programs receive blind samples at defined intervals, analyze them under routine conditions, and report results that are statistically compared to peer performance. Outlier results prompt required corrective actions that must be documented and verified. This ongoing performance benchmarking provides the surveillance function that prevents analytical drift from going undetected between inspection cycles.
As of March 2024, 6,433 non-exempt US laboratories held CAP certificates of accreditation, making CAP the largest CMS-recognized accreditation organization in the United States for laboratory accreditation purposes, ahead of COLA with 6,017 laboratories and The Joint Commission with 1,961. Globally, CAP serves laboratories in over 100 countries through its accreditation and proficiency testing programs, providing an international quality infrastructure that parallels ISO 15189 in many markets.
ISO 15189: The International Quality Standard
ISO 15189, “Medical Laboratories: Requirements for Quality and Competence,” is the international standard developed by ISO Technical Committee 212 that defines what a medical laboratory must demonstrate to be considered competent and quality-assured in the eyes of the global healthcare and regulatory community. Unlike CLIA, which is a domestic legal requirement, and unlike CAP, which is a voluntary accreditation offered by a professional organization, ISO 15189 is a consensus standard developed through an international standards process involving national standardization bodies from over 160 countries. It carries no legal force in most jurisdictions, but its acceptance through ILAC mutual recognition arrangements means that ISO 15189 accreditation provides internationally portable evidence of laboratory competence that no single national framework can fully replicate.
The fourth and current edition, ISO 15189:2022, represents the most comprehensive revision of the standard since 2003. It restructured its requirements to align with ISO/IEC 17025:2017 by placing management requirements at the end of the document and foregrounding technical requirements. It incorporated the requirements of ISO 22870:2016 for point-of-care testing directly into the main standard, leading to the withdrawal of ISO 22870:2016 as a standalone document. It introduced substantially stronger requirements for risk-based thinking throughout the quality management system, aligned with ISO 22367 on risk management for medical laboratories. And it introduced fifteen new terms and definitions that standardize the vocabulary of laboratory quality management internationally, covering concepts including measurement uncertainty, bias, impartiality, and laboratory user.
The ILAC transition period for ISO 15189:2022 ran from December 2022 to December 6, 2025, by which date all effective clinical laboratory accreditations worldwide were required to demonstrate compliance with the 2022 version rather than its 2012 predecessor. This deadline affected laboratories in every ILAC member country and drove substantial preparation work throughout 2023, 2024, and 2025, particularly in laboratories needing to strengthen their documentation of risk management, measurement uncertainty, and point-of-care testing governance.
In the United States, ISO 15189 accreditation is not recognized by CMS as meeting CLIA requirements. A US laboratory pursuing ISO 15189 accreditation must maintain its CLIA certificate separately, making ISO 15189 an additive rather than a substitutive credential in the American regulatory environment. The accreditation organization A2LA has achieved the distinction of being the only accreditation body in the world to hold both CMS-deemed status for CLIA and ILAC recognition for ISO 15189, offering a “Platinum Choice” combined assessment that allows qualifying laboratories to demonstrate compliance with both frameworks through a single inspection process. This option directly addresses the practical burden of maintaining separate compliance documentation for parallel accreditation programs.
For laboratories outside the United States, particularly in regions where ISO 15189 accreditation is the primary or sole recognized quality credential, the standard functions analogously to what CLIA and CAP together accomplish in the US: establishing minimum competence requirements, driving proficiency testing participation, requiring documented quality management systems, and providing the basis for independent verification of laboratory quality through accreditation body assessment.
How the Three Frameworks Relate and Differ
The relationship between CLIA, CAP, and ISO 15189 can be understood as three layers of quality assurance operating at different levels of scope and rigor, with significant but imperfect overlap.
CLIA establishes the legally mandatory floor. No US laboratory testing human specimens can operate without it, and its requirements define minimum personnel qualifications, quality control procedures, proficiency testing enrollment, and reporting standards. It is specific to the United States, administered by federal agencies, and primarily focused on testing operations at a relatively detailed technical level. The 317,545 laboratories in the CLIA database range from simple waived-test facilities in retail pharmacies to academic medical center reference laboratories processing millions of specimens annually, and the calibrated complexity framework attempts to apply proportionate oversight across that enormous range.
CAP builds a second, voluntary layer above CLIA. It applies primarily to higher-complexity laboratories, demands more comprehensive quality documentation, conducts more rigorous peer inspections, maintains a broader proficiency testing catalog, and drives continuous quality improvement through evidence-based checklist updates. A laboratory that achieves CAP accreditation has voluntarily demonstrated competence substantially beyond the legal minimum, and the globally recognized status of CAP accreditation provides a credibility signal that is meaningful in clinical partnerships, research collaborations, and competitive differentiation.
ISO 15189 adds an internationally portable dimension to laboratory quality credentials. Its quality management system requirements are in many respects broader than CLIA’s and parallel to CAP’s at the analytical and documentation level, but with a stronger and more explicitly articulated upper-management governance framework, a greater emphasis on risk management as an integrated QMS function, and a global validity through ILAC mutual recognition that neither CLIA nor CAP can match. For US laboratories participating in multinational clinical trials, providing reference laboratory services to international healthcare organizations, or seeking recognition in markets where ISO 15189 is the local reimbursement or regulatory standard, ISO 15189 accreditation addresses a need that CLIA and CAP alone do not.
All three frameworks converge on the same ultimate objectives: accurate, reliable laboratory results produced by competent personnel using validated methods under documented quality systems, delivered to clinicians in time to affect patient management. They differ in their geographic scope, their legal authority, the depth of their quality management requirements, and the mechanisms through which compliance is assessed. For laboratories navigating these frameworks, understanding how they complement and differ from one another is the foundation for building a quality program that meets all applicable requirements while recognizing where each standard adds genuine clinical and operational value.
What Accreditation Means for Patients and Laboratory Professionals
From the patient’s perspective, laboratory accreditation operates invisibly but consequentially. A patient who submits a blood sample to a CAP-accredited laboratory is relying on an infrastructure of peer inspections, proficiency testing, documented procedures, personnel competency assessments, and quality control programs that they know nothing about but that directly determine whether the result they receive is accurate and whether the clinical decision made on that result is well-founded.
For laboratory professionals, accreditation standards define the professional standards of practice. Personnel qualification requirements establish what education and training are needed to perform specific types of testing. Competency assessment requirements establish how performance must be documented and remediated, which is why ongoing continuing education is woven into the requirements of all three frameworks. Quality indicator requirements establish what must be measured and how it must be acted upon. And the proficiency testing programs required by all three frameworks provide the external benchmarking that tells laboratory professionals whether their methods are performing as they should in comparison to peer laboratories worldwide.
Bio-Reach’s commitment to advancing laboratory medicine globally is directly relevant to this landscape. The laboratories with the most critical need for quality frameworks, in low- and middle-income countries where diagnostic capacity determines the difference between life and death for patients with HIV, tuberculosis, malaria, and emerging infectious diseases, are often those with the least institutional history of formal accreditation. ISO 15189-based programs like SLIPTA and SLMTA, which have been described in the quality management system literature, have demonstrated that structured accreditation pathways produce measurable improvements in laboratory performance in exactly these settings. The laboratory accreditation standards discussed in this article are not bureaucratic requirements for wealthy healthcare systems. They are the infrastructure of trustworthy diagnosis, and the case for expanding their reach is a case for global health equity.
Conclusion
CLIA, CAP, and ISO 15189 represent complementary but distinct frameworks for laboratory accreditation, each serving a specific role in the quality infrastructure of clinical laboratory medicine. CLIA is the legally mandatory federal baseline for all US clinical laboratories, defining minimum requirements across the full spectrum of testing complexity. CAP is the voluntary accreditation program that the majority of complex US laboratories pursue because its standards exceed CLIA requirements, its peer inspection model provides meaningful quality benchmarking, and its global recognition signals a level of quality commitment that CLIA compliance alone does not. ISO 15189 is the internationally recognized standard that provides globally portable evidence of laboratory competence, whose 2022 revision deepened requirements for risk management, point-of-care testing governance, and quality management system integration.
Together, these frameworks have produced the regulated laboratory ecosystem that processes hundreds of billions of tests annually, influencing an estimated 70 percent of all clinical decisions in the process. Understanding what each standard requires, how they relate to one another, and where they do and do not substitute for each other is the knowledge base from which laboratory professionals can build quality programs that are not merely compliant but genuinely effective.
Bio-Reach is a non-profit organization dedicated to advancing Laboratory Medicine through advocacy, education, and global collaboration. To learn more or get involved, visit bio-reach.org.
